Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11786558-B2

Patent

Publication Date

2023-10-17

Expiration Date


Abstract

Described herein are methods of cell therapies. Also described herein are methods of generating donor derived T cells in an organ transplant recipient, by administering bone marrow stem cells to the organ transplant recipient about 1 to about 30 days after the organ transplant recipient receives one or more organ transplants.

Core Innovation

The claimed method manages immune outcomes in a subject who has received an intestinal transplant. It generates a lymphohematopoietic graft-versus-host response and subsequently administers a selected population of CD34+ cells with limited CD3+ cell content. These steps establish mixed chimerism or T-cell macrochimerism, prevent a host-versus-graft response, and prevent donor organ rejection, with further selection details being [procedural detail omitted for safety].

The disclosure evaluates donor CD34+ cell infusion during maximal lymphohematopoietic graft-versus-host response after intestinal or multivisceral transplantation to promote durable multilineage chimerism and graft protection. Reported findings associate donor T-cell macrochimerism with reduced rejection and donor-specific antibody development, without observed graft-versus-host disease in the described cohort. Disclosures also identify donor-derived hematopoietic progenitors, graft-versus-host-reactive T-cell clones, and dynamic B-cell populations.

Claims Coverage

The claims identify one independent claim comprising two inventive features directed to managing immune outcomes in an intestinal-transplant recipient.

Generation of a lymphohematopoietic graft-versus-host response and administration of selected CD34+ cells

In a subject who has received an intestinal transplant, the method generates a lymphohematopoietic graft-versus-host response and subsequently administers a population of CD34+ cells selected to limit CD3+ cells, wherein selection details are [procedural detail omitted for safety].

Establishment of chimerism or prevention of transplant rejection

The method establishes mixed chimerism or T-cell macrochimerism, prevents a host-versus-graft response, and/or prevents rejection of the donor organ.

The independent claim combines the generation of a lymphohematopoietic graft-versus-host response with response-triggered administration of selected CD34+ cells to establish chimerism and prevent adverse transplant immune outcomes.

Stated Advantages

Establishes mixed chimerism or T-cell macrochimerism in an intestinal transplant recipient.

Prevents a host-versus-graft response and/or prevents rejection of the donor organ.

Associates donor T-cell macrochimerism with reduced rejection and donor-specific antibody development, without observed graft-versus-host disease in the multivisceral-transplant cohort.

Documented Applications

Application in a subject who has received an intestinal transplant.

Monitoring and evaluation of cellular chimerism, immune responses, and application in multivisceral transplantation.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.